The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
 
YANYAN LIU
No Relationships to Disclose
 
Ningjing Lin
No Relationships to Disclose
 
Zhihua Yao
No Relationships to Disclose
 
Jiuyang Zhang
No Relationships to Disclose
 
Wei Meng
Employment - ImmuneOnco Biopharmaceuticals
 
Zhenjiu Wang
Employment - ImmuneOnco Biopharmaceuticals
 
Qiying Lu
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals
 
Wenzhi Tian
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals (Inst)
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals (Inst)
 
Yuqin Song
No Relationships to Disclose
 
Jun Zhu
No Relationships to Disclose